Retatrutide 20mg

Description

Retatrutide 20 mg is a higher-concentration format of the triple-agonist peptide Retatrutide. Each vial contains 20 mg of lyophilized peptide for research applications requiring larger working stock.

Research Profile

• Triple-agonist activity across GIP, GLP-1, and glucagon receptors
• Studied in metabolic, energy-balance, and glucose-handling research models
• Larger vial format for high-throughput studies
• QC verified by HPLC and mass spectrometry

Specifications

• Compound: Retatrutide (LY3437943)
• Dosage: 20 mg per vial
• Purity: ≥ 98% (HPLC)
• Form: Lyophilized powder
• Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.